You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

trastuzumab

( trass-TOO-zoo-mab )
Funding:
Evidence Building Program
  • Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
  • Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
  • Trastuzumab (Biosimilar) with First Line Docetaxel - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) in combination with Vinorelbine - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) in combination with Docetaxel - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) - Single Agent - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer
  • Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
  • Trastuzumab (Biosimilar) in combination with Paclitaxel - Metastatic Breast Cancer
... Show more tags
Other Name(s): Herceptin®; Kanjinti™; Ogivri™; Trazimera™; Herzuma®
Appearance: Clear, colourless solution mixed into larger bags of fluids

Drug Monograph

Aug 2020
Table of Contents
Eligibility Forms
pdf download Pertuzumab-Trastuzumab - Unresectable Locally Recurrent or Metastatic - Breast Cancer pdf download Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer pdf download Trastuzumab (Biosimilar) - Single Agent - Metastatic Breast Cancer pdf download Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental pdf download Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer pdf download Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer pdf download Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer pdf download Trastuzumab (Biosimilar) in combination with Docetaxel - Metastatic Breast Cancer pdf download Trastuzumab (Biosimilar) in combination with Paclitaxel - Metastatic Breast Cancer pdf download Trastuzumab (Biosimilar) in combination with Vinorelbine - Metastatic Breast Cancer pdf download Trastuzumab (Biosimilar) with First Line Docetaxel - Metastatic Breast Cancer

Patient Info Sheet

Jun 2021

What it is used for

For treating certain types of breast, stomach or esophagus cancers, and others

Trastuzumab is available as a biosimilar medication. See our biosimilar pamphlet for more information. 



You might also be interested in

Funding & Reimbursement

Several payment sources exist for cancer drugs in Ontario, depending on the drug, disease indication, and how and where it is delivered.

View Funding & Reimbursement

Symptom Management

Many people living with cancer experience nausea, diarrhea and other symptoms from their treatment or disease.

View Symptom Management

Drug Safety and Administration

Find documents on drug safety and administration for healthcare providers, including calculations and recommendations.

View Drug Safety and Administration